Patent · US Active

Drug delivery formulations

US12383493B2 · kind B2 · utility

0Cited by
2References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 11, 2020
Grant dateAug 12, 2025
Priority date
Expiry dateSep 7, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P25/18
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.